Cantoni Therapeutics

Executive Summary

Cantoni Therapeutics is a private Dutch biotechnology company focused on developing best-in-class small molecule inhibitors of nicotinamide N-methyltransferase (NNMT), a novel target for cardiometabolic diseases and other indications. Founded in 2021 and based in Amsterdam, the company is in the early stages of drug discovery, with no disclosed funding or clinical stage. NNMT inhibition represents a promising approach to modulate energy metabolism and reduce disease progression, but the field is still preclinical. Cantoni's success hinges on advancing lead candidates through preclinical validation, securing partnerships, and initiating clinical trials. Given the early stage, significant execution risks remain, but the target's novelty offers potential for first-in-class therapies in a large unmet need area.

Upcoming Catalysts (preview)

• 2026 Q4Preclinical Proof-of-Concept Data Release40% success
• 2027 Q1Series A Financing Round50% success
• 2027 Q2Lead Optimization and IND-Enabling Studies Initiation30% success